In Brief: Trimedyne laser patent
This article was originally published in The Gray Sheet
Trimedyne laser patent: U.S. Patent and Trademark Office affirms the validity of Trimedyne's "key laser patent" (No. 5,387, 211) covering a multi-head laser assembly used in its OmniPulse-MAX holmium laser, the Irvine, California firm announces. Laser Industries, Inc. filed a petition with PTO in February 1995 asking for a review of the '211 patent. Trimedyne notes that Laser Industries has the right to appeal the PTO decision, but "in light of the PTO's emphatic denial" of the petition, the company "does not believe an appeal would likely be successful"...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.